These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23550992)

  • 21. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
    Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
    Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
    Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen L
    Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):250-3. PubMed ID: 15622757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARĪ± protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Sui M; Zhang Z; Zhou J
    Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
    Dillon R; Grimwade D
    Leuk Lymphoma; 2014 Jul; 55(7):1444-6. PubMed ID: 24313832
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
    Westervelt P; Pollock JL; Oldfather KM; Walter MJ; Ma MK; Williams A; DiPersio JF; Ley TJ
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9468-73. PubMed ID: 12077315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
    Ammatuna E; Montefusco E; Pacilli M; Divona M; Ardiri D; Centonze D; Lo-Coco F
    Leuk Lymphoma; 2009 Jul; 50(7):1217-8. PubMed ID: 19479616
    [No Abstract]   [Full Text] [Related]  

  • 31. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
    Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
    Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
    Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
    Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
    Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
    J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

  • 36. The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
    Salerno M; Petroutsa M; Garnier-Suillerot A
    J Bioenerg Biomembr; 2002 Apr; 34(2):135-45. PubMed ID: 12018890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic trioxide: expanding roles for an ancient drug?
    Ravandi F
    Leukemia; 2004 Sep; 18(9):1457-9. PubMed ID: 15269784
    [No Abstract]   [Full Text] [Related]  

  • 38. Arsenicals in hematologic cancers.
    Novick SC; Warrell RP
    Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
    Sahu GR; Jena RK
    Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.